References
- Petrou S, Henderson J, Roberts T, Martin MA. Recent economic evaluations of antenatal screening: a systematic review and critique. J. Med. Screen.7(2), 59–73 (2000).
- Petrou S. Methodological limitations of economic evaluations of antenatal screening. Health. Econ.10(8), 775–778 (2001).
- Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J. Med. Screen.10(2), 56–104 (2003).
- Mooney G, Lange M. Ante-natal screening: what constitutes ‘benefit’? Soc. Sci. Med.37, 873–878 (1993).
- Walker M, Pandya P. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach. Obstet. Gynecol.96(3), 481 (2000).
- Cusick W, Buchanan P, Hallahan TW, Krantz DA, Larsen JW Jr, Macri JN. Combined first-trimester versus second-trimester serum screening for Down syndrome: a cost analysis. Am. J. Obstet. Gynecol.188(3), 745–751 (2003).
- Spencer K, Aitken D. Factors affecting women’s preference for type of prenatal screening test for chromosomal anomalies. Ultrasound Obstet. Gynecol.24(7), 735–739 (2004).
- de Graaf IM, Tijmstra T, Bleker OP, van Lith JM. Womens’ preference in Down syndrome screening. Prenat. Diagn.22(7), 624 (2002).
- Feeny D, Tomkins DJ. Health-related quality of life in prenatal diagnosis. Expert Rev. Pharmacoeconomics Outcomes Res.4(2), 207 (2004).
- Harris RA, Washington AE, Feeny D, Kuppermann M. Decision analysis of prenatal testing for chromosomal disorders: what do the preferences of pregnant women tell us? Genet. Test.5(1), 23–32 (2001).
- Harris RA, Washington AE, Nease RF Jr, Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet363, 276–282 (2004).
- Kuppermann M, Nease RF, Learman LA, Gates E, Blumberg B, Washington AE Procedure-related miscarriages and Down syndrome-affected births: implications for prenatal testing based on women’s preferences. Obstet. Gynecol.96(4), 511–516 (2000).
- Petrou S, Mugford M. Should prenatal diagnostic testing be offered to all pregnant women on economic grounds? Lancet363(9405), 258–259 (2004).
- Mulvey S, Zachariah R, McIlwaine K, Wallace EM. Do women prefer to have screening tests for Down syndrome that have the lowest screen-positive rate or the highest detection rate? Prenat. Diagn.23(10), 828–832 (2003).
- Felder S, Werblow A, Robra BP. A priori risk and optimal test accuracy in prenatal diagnostics. Med. Decis. Making23(5), 406–413 (2003).
- Benn PA, Horne D, Briganti S, Greenstein RM. Prenatal diagnosis of diverse chromosome abnormalities in a population of patients identified by triple-marker testing as screen positive for Down syndrome. Am. J. Obstet. Gynecol.173(2), 496–501 (1995).
- Conseil d’Evaluation des Technologies de la Santé du Québec. Les enjeux du dépistage et du diagnostic prénatals du syndrome de Down. Montréal CETS 99–4 RF (1999).
- Arrow K. Uncertainty and the welfare economics of medical care. Am. Econ. Rev.53, 941–973 (1963).
Websites
- Harvard Center for Risk Analysis. Risk in Perspective. www.hcra.harvard.edu/pdf/dec04.pdf
- www.mrw.interscience.wiley.com/cochrane/cleed/articles/NSHEED-20030632
- WHO Revised Global Burden of Disease (GBD) 2002 Estimates. www.who.int/healthinfo/bodgbd2002revised/en/index.html
- Eurordiscare survey 2002–2003 report. www.eurordis.org/article.php3?id_article=453&var_
- Evidence-Based Medicine Guidelines. www.ebm-guidelines.com/ebmg/ltk.koti